Neurogene Inc.
Support and Resistance Levels
Past performance
News About NGNE
All events for NGNE
All deals for NGNE
Financial Ratios
Financial Statements
NGNE vs Sector & Peers
About Neurogene Inc.
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York. Website neurogene.com
Headquarters New York City, NY, US